Skip to main content

Table 3 Moderate intensity of front-line therapy for young fit patient with mantle cell lymphoma

From: Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy

Regimen Series No. Age(ys) Median (range) MIPI Low/Int/High(%) ORR (%) CR (%) mFU (ms) mPFS (ms) mOS (ms) TRM (%) Second malignancy(%)
Bort-DA-EPOCH-R ± Bort Dunleavy (2012) [42] 43 58(41–73) 50/37/13 92 63 48 50% (4-y PFS) 80% (4-y OS) na na
DA-EPOCH-R + vaccine Grant (2011) [41, 67] 26 57 (22–73) 65/16/19 100 92 11ys 24 104 na na
RB/RC Armand(2016) [43] 23 57 (42–69) 70/22/9 96 96 13 96% (1-y PFS) 96% (1-y OS) 0 na
R 2 Ruan (2015) [60] 38 65(42–86) 34/34/32 92 64 30 85% (2-y PFS) 97% (2-y OS) 0 23.3
R-CHOP+ Zevalin Smith(2007) [45, 46] 56 61 (33–83) 50/27/12 74 42 9.8ys na 56% at 10 ys (age ≤ 65) 0 10.7
  1. Abbreviations as indicated in the Tables 1 and 2
  2. Note: Bort Bortezomib, DA-EPOCH dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, RB/RC rituximab/bendamustine+ rituximab/high-dose cytarabine; R2 rituximab plus lenalidomide;